AR127163A1 - Anticuerpos dirigidos a baff-r y uso de estos - Google Patents
Anticuerpos dirigidos a baff-r y uso de estosInfo
- Publication number
- AR127163A1 AR127163A1 ARP220102598A ARP220102598A AR127163A1 AR 127163 A1 AR127163 A1 AR 127163A1 AR P220102598 A ARP220102598 A AR P220102598A AR P220102598 A ARP220102598 A AR P220102598A AR 127163 A1 AR127163 A1 AR 127163A1
- Authority
- AR
- Argentina
- Prior art keywords
- cell
- proteins
- nucleic acid
- antigen binding
- binding site
- Prior art date
Links
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 title abstract 2
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 abstract 1
- 239000012642 immune effector Substances 0.000 abstract 1
- 229940127130 immunocytokine Drugs 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000581 natural killer T-cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se divulgan proteínas con dominios variables de cadena ligera y cadena pesada de anticuerpos que se pueden aparear para formar un sitio de unión a antígeno dirigido a BAFF-R en una célula, composiciones farmacéuticas que comprenden tales proteínas y métodos terapéuticos que utilizan tales proteínas y composiciones farmacéuticas, que incluyen para el tratamiento del cáncer o una enfermedad autoinmunitaria. Reivindicación 32: Un conjugado de anticuerpo-fármaco que comprende la proteína de cualquiera de las reivindicaciones 22 - 31 y un resto de fármaco. Reivindicación 34: Una inmunocitocina que comprende el sitio de unión a antígeno de cualquiera de las reivindicaciones 1 - 21 y una citocina. Reivindicación 42: Un ácido nucleico aislado que codifica el CAR de cualquiera de las reivindicaciones 37 - 41. Reivindicación 43: Un vector de expresión que comprende el ácido nucleico aislado de la reivindicación 42. Reivindicación 47: La célula efectora inmunitaria de la reivindicación 46, en donde el linfocito T es un linfocito T CD8⁺, un linfocito T CD4⁺, un linfocito T gd o una célula NKT.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163250092P | 2021-09-29 | 2021-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127163A1 true AR127163A1 (es) | 2023-12-27 |
Family
ID=85780903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102598A AR127163A1 (es) | 2021-09-29 | 2022-09-27 | Anticuerpos dirigidos a baff-r y uso de estos |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR127163A1 (es) |
| AU (1) | AU2022354054A1 (es) |
| CA (1) | CA3233246A1 (es) |
| IL (1) | IL311600A (es) |
| TW (1) | TW202330604A (es) |
| WO (1) | WO2023056243A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010072741A1 (en) * | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREFOR |
| WO2009120922A2 (en) * | 2008-03-27 | 2009-10-01 | Zymogenetics, Inc. | Compositions and methods for inhibiting pdgfrbeta and vegf-a |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| WO2017214170A2 (en) * | 2016-06-06 | 2017-12-14 | City Of Hope | Baff-r antibodies and uses thereof |
-
2022
- 2022-09-27 TW TW111136545A patent/TW202330604A/zh unknown
- 2022-09-27 AR ARP220102598A patent/AR127163A1/es unknown
- 2022-09-27 IL IL311600A patent/IL311600A/en unknown
- 2022-09-27 CA CA3233246A patent/CA3233246A1/en active Pending
- 2022-09-27 AU AU2022354054A patent/AU2022354054A1/en active Pending
- 2022-09-27 WO PCT/US2022/077068 patent/WO2023056243A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| TW202330604A (zh) | 2023-08-01 |
| CA3233246A1 (en) | 2023-04-06 |
| AU2022354054A1 (en) | 2024-03-28 |
| IL311600A (en) | 2024-05-01 |
| WO2023056243A1 (en) | 2023-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klareskog et al. | Epidermal Langerhans cells express Ia antigens | |
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| MY189113A (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| CO2020010345A2 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
| EA201891670A1 (ru) | Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака | |
| EA202091754A1 (ru) | Пептиды и комбинации пептидов неканонического происхождения для применения в иммунотерапии различных видов рака | |
| BRPI0314038B8 (pt) | anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica | |
| EA201992765A1 (ru) | Белки на основе антител с привитым цитокином и способы их применения в лечении рака | |
| ATE248858T1 (de) | Therapeutische konjugate von toxinen und medikamenten | |
| Huber et al. | Immmunotherapy of cancer: from vision to standard clinical practice | |
| ES2429422A2 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
| Wang et al. | Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade | |
| BR112023001733A2 (pt) | Anticorpos anti-ceacam5 e conjugados e usos dos mesmos | |
| BR112022006817A2 (pt) | Anticorpos direcionados a flt3 e uso dos mesmos | |
| Nguyen et al. | Th1/Th17 T cell tissue-resident immunity increases protection, but is not required in a vaccine strategy against genital infection with chlamydia trachomatis | |
| AR127163A1 (es) | Anticuerpos dirigidos a baff-r y uso de estos | |
| BR112022022418A2 (pt) | Anticorpos de alvejamento de clec12a e uso dos mesmos | |
| CR20230259A (es) | Anticuerpos de cadena pesada que se unen al receptor de folato alfa | |
| Schmid et al. | Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads | |
| Penna et al. | Antitumor× anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases | |
| BR112023002150A2 (pt) | Anticorpos direcionando egfr e uso dos mesmos | |
| AR123091A1 (es) | ANTICUERPOS ANTI-IL13Ra2 | |
| Kim et al. | Overview analysis of adjuvant therapies for melanoma—a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials | |
| Asgary et al. | Evaluation of the effect of silver nanoparticles on induction of neutraliz-ing antibodies against inactivated Rabies virus | |
| Li et al. | Induction of CD4+ regulatory T cells by stimulation with Staphylococcal Enterotoxin C2 through different signaling pathways |